Buy LTRN by Sep 11, 2026.

Most investors look at Lantern Pharma as a small oncology biotech. But what if the market is missing the platform value? Lantern today has: • LP-300 in Phase 2 for never-smoker NSCLC (HARMONIC trial)  • LP-184 advancing across multiple solid tumors and CNS cancers, including GBM, pancreatic cancer and brain metastases  • LP-284 in clinical development for relapsed/refractory lymphomas  • An ADC program in development  • The proprietary RADR® AI platform, used to identify patient populations, …